Global Immune Thrombocytopenia Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Immune Thrombocytopenia Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood.
Immune Thrombocytopenia Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Immune Thrombocytopenia Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Biotechnology and Pharmaceutical Companies and Hospitals and Diagnostic Centers are the major drivers for the industry.
End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for approval. The upcoming expiration of patents in the immune thrombocytopenia drugs market will fuel the development of biosimilars for those products. For instance, the forthcoming expiration of patents of Nplate (romiplostim) and rituximab has encouraged market vendors to develop their biosimilars. This will also create several opportunities for new vendors to enter the market. Hence, the growing popularity and development of biosimilars will augment the growth of the immune thrombocytopenia drugs market throughout the next five years.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Immune Thrombocytopenia Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Amgen Inc.
CSL Ltd.
Horizon Therapeutics Plc
Merck & Co., Inc.
Novartis AG
Rigel Pharmaceuticals Inc.
Segment by Type
Thrombopoietin Receptor Agonists (TPO-RAs)
Corticosteroids
Intravenous Immunoglobins (IVIGs)
Other Drugs
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Centers
Academic Institutes and Research Organizations
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Immune Thrombocytopenia Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Immune Thrombocytopenia Drugs introduction, etc. Immune Thrombocytopenia Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Immune Thrombocytopenia Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Immune Thrombocytopenia Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Immune Thrombocytopenia Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Biotechnology and Pharmaceutical Companies and Hospitals and Diagnostic Centers are the major drivers for the industry.
End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for approval. The upcoming expiration of patents in the immune thrombocytopenia drugs market will fuel the development of biosimilars for those products. For instance, the forthcoming expiration of patents of Nplate (romiplostim) and rituximab has encouraged market vendors to develop their biosimilars. This will also create several opportunities for new vendors to enter the market. Hence, the growing popularity and development of biosimilars will augment the growth of the immune thrombocytopenia drugs market throughout the next five years.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Immune Thrombocytopenia Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Amgen Inc.
CSL Ltd.
Horizon Therapeutics Plc
Merck & Co., Inc.
Novartis AG
Rigel Pharmaceuticals Inc.
Segment by Type
Thrombopoietin Receptor Agonists (TPO-RAs)
Corticosteroids
Intravenous Immunoglobins (IVIGs)
Other Drugs
Segment by Application
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Centers
Academic Institutes and Research Organizations
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Immune Thrombocytopenia Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Immune Thrombocytopenia Drugs introduction, etc. Immune Thrombocytopenia Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Immune Thrombocytopenia Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices